0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Viewpoint | 
Peter C. Adamson, MD
JAMA Pediatr. 2013;167(10):886-887. doi:10.1001/jamapediatrics.2013.2488.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Original Investigation  | 
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, MD, PhD; David Venet, PhD; Michail Ignatiadis, MD, PhD; et al.
JAMA Oncology
Viewpoint  | 
The Trade-off Between Speed and Safety in Drug Approvals
Anupam B. Jena, MD, PhD; Jie Zhang, PhD; Darius N. Lakdawalla, PhD
JAMA Oncology
Viewpoint  | 
Highlights in Gastrointestinal (Colorectal) Cancer Treatment The Primary Tumor Sidedness Debate and Advances in Immunotherapy
Kristen K. Ciombor, MD, MSCI; Richard M. Goldberg, MD
JAMA Oncology
Original Investigation  | 
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh Score
Andrew X. Zhu, MD, PhD; Ari David Baron, MD; Peter Malfertheiner, MD; et al.